Cargando…

Molecular Docking and Prediction of Pharmacokinetic Properties of Dual Mechanism Drugs that Block MAO-B and Adenosine A(2A) Receptors for the Treatment of Parkinson's Disease

Monoamine oxidase B (MAO-B) inhibitory potential of adenosine A(2A) receptor (AA(2A)R) antagonists has raised the possibility of designing dual-target–directed drugs that may provide enhanced symptomatic relief and that may also slow the progression of Parkinson's disease (PD) by protecting aga...

Descripción completa

Detalles Bibliográficos
Autores principales:	Azam, Faizul, Madi, Arwa M., Ali, Hamed I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2012
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483529/ https://www.ncbi.nlm.nih.gov/pubmed/23112538 http://dx.doi.org/10.4103/0975-1483.100027

Ejemplares similares

Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology
por: Finberg, John P. M., et al.
Publicado: (2016)

Highly Variable Pharmacokinetics of Tyramine in Humans and Polymorphisms in OCT1, CYP2D6, and MAO-A
por: Rafehi, Muhammad, et al.
Publicado: (2019)

Molecular docking studies of 1-(substituted phenyl)-3-(naphtha [1, 2-d] thiazol-2-yl) urea/thiourea derivatives with human adenosine A(2A) receptor
por: Azam, Faizul, et al.
Publicado: (2011)

MAO-inhibitors in Parkinson's Disease
por: Riederer, Peter, et al.
Publicado: (2011)

Structure-based design, synthesis, molecular docking, and biological activities of 2-(3-benzoylphenyl) propanoic acid derivatives as dual mechanism drugs
por: Ahmed, Musa A., et al.
Publicado: (2012)

Population Pharmacokinetic Properties of Antituberculosis Drugs in Vietnamese Children with Tuberculous Meningitis
por: Panjasawatwong, Navarat, et al.
Publicado: (2020)

Editorial: Pharmacokinetic differences of drugs and their regulatory mechanisms under dual status including normal and diseased organism
por: Gong, Zipeng, et al.
Publicado: (2022)

Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension
por: Alencar, Allan K. N., et al.
Publicado: (2017)

Novel Series of Dual NRF2 Inducers and Selective MAO-B Inhibitors for the Treatment of Parkinson’s Disease
por: Duarte, Pablo, et al.
Publicado: (2022)

Molecular Evidence of Adenosine Deaminase Linking Adenosine A(2A) Receptor and CD26 Proteins
por: Moreno, Estefanía, et al.
Publicado: (2018)

Adenosine in the Thymus
por: Köröskényi, Krisztina, et al.
Publicado: (2017)

Drug Transporters in the Kidney: Perspectives on Species Differences, Disease Status, and Molecular Docking
por: Zou, Wei, et al.
Publicado: (2021)

Maó
por: Quintana, Josep M. (Josep Maria)
Publicado: (1996)

Molecular docking analysis and dynamics simulation of salbutamol with the monoamine oxidase B (MAO-B) enzyme
por: Abdulhameed Odhar, Hasanain, et al.
Publicado: (2022)

Docking Screens for Dual Inhibitors of Disparate Drug Targets for Parkinson’s Disease
por: Jaiteh, Mariama, et al.
Publicado: (2018)

Adenosine Kinase on Deoxyribonucleic Acid Methylation: Adenosine Receptor-Independent Pathway in Cancer Therapy
por: Luo, Hao-Yun, et al.
Publicado: (2022)

Preclinical Pharmacokinetics and In Vitro Properties of GS-441524, a Potential Oral Drug Candidate for COVID-19 Treatment
por: Wang, Amy Q., et al.
Publicado: (2022)

Who Is Who in Adenosine Transport
por: Pastor-Anglada, Marçal, et al.
Publicado: (2018)

Mao : a biography /
por: Terrill, Ross
Publicado: (1981)

Corrigendum: Adenosine kinase on deoxyribonucleic acid methylation: Adenosine receptor-independent pathway in cancer therapy
por: Luo, Hao-Yun, et al.
Publicado: (2023)

Synthesis and Evaluation of Phenylxanthine Derivatives as Potential Dual A2AR Antagonists/MAO-B Inhibitors for Parkinson’s Disease
por: Wang, Xuebao, et al.
Publicado: (2017)

Mao Zedong
por: Grimm, Tilemann
Publicado: (1986)

Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson’s Disease with Neuroprotective Potential
por: Finberg, John P.M.
Publicado: (2010)

Editorial: Pharmacokinetics of herbal medicines and herb-drug interactions
por: Jia, Wei-Wei, et al.
Publicado: (2022)

Comorbid epilepsy and depression—pharmacokinetic and pharmacodynamic drug interactions
por: Miziak, Barbara, et al.
Publicado: (2022)

Effects of bariatric surgery on drug pharmacokinetics—Preclinical studies
por: Mercado, Angela, et al.
Publicado: (2023)

The Role of Adenosine Receptors in Psychostimulant Addiction
por: Ballesteros-Yáñez, Inmaculada, et al.
Publicado: (2018)

ATP and Adenosine in the Retina and Retinal Diseases
por: Ye, Shan-Shan, et al.
Publicado: (2021)

Metabolic Aspects of Adenosine Functions in the Brain
por: Garcia-Gil, Mercedes, et al.
Publicado: (2021)

MAO-B Elevation in Mouse Brain Astrocytes Results in Parkinson's Pathology
por: Mallajosyula, Jyothi K., et al.
Publicado: (2008)

Rasagiline – a novel MAO B inhibitor in Parkinson’s disease therapy
por: Lecht, Shimon, et al.
Publicado: (2007)

A critical appraisal of MAO-B inhibitors in the treatment of Parkinson’s disease
por: Jost, Wolfgang H.
Publicado: (2022)

Targeting SARS-CoV-2 main protease by teicoplanin: A mechanistic insight by docking, MM/GBSA and molecular dynamics simulation
por: Azam, Faizul, et al.
Publicado: (2021)

Discovery of MAO-B Inhibitor with Machine Learning, Topomer CoMFA, Molecular Docking and Multi-Spectroscopy Approaches
por: Zheng, Linfeng, et al.
Publicado: (2022)

Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug–Drug and Drug–Disease Interactions of Apatinib
por: Liu, Hongrui, et al.
Publicado: (2021)

Hydroxysafflor Yellow A: A Systematical Review on Botanical Resources, Physicochemical Properties, Drug Delivery System, Pharmacokinetics, and Pharmacological Effects
por: Zhao, Feng, et al.
Publicado: (2020)

The evaluation of ADME and pharmacokinetic properties of decoquinate derivatives for the treatment of malaria
por: Watson, Daniel J., et al.
Publicado: (2022)

Study on the Neuroprotective, Radical-Scavenging and MAO-B Inhibiting Properties of New Benzimidazole Arylhydrazones as Potential Multi-Target Drugs for the Treatment of Parkinson’s Disease
por: Anastassova, Neda, et al.
Publicado: (2022)

Molecular determinants of acrylamide neurotoxicity through covalent docking
por: Mueller, Nicolas Pierre Friedrich, et al.
Publicado: (2023)

Novel 1,2,3-Triazole Erlotinib Derivatives as Potent IDO1 Inhibitors: Design, Drug-Target Interactions Prediction, Synthesis, Biological Evaluation, Molecular Docking and ADME Properties Studies
por: Xu, Gui-Qing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qfffi3evi5f51e30ga8nu805f1